Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).
暂无分享，去创建一个
G. Beretta | J. Tabernero | M. Alsina | H. Arkenau | D. Ganea | M. Dvorkin | V. Gorbunova | A. Hosokawa | D. Ilson | K. Shitara | K. Fujitani | R. Winkler | E. Zhavrid | K. Nishikawa | W. Mansoor | M. Ghidini | L. Makris | T. Doi | A. Prokharau | C. Faustino | Ş. Yalçın